Enantioselective plasma protein binding of propafenone: Mechanism, drug interaction, and species difference

Chirality

Volumn 21, Issue 7, 2009, Pages 692-698

  Hong, Yanjun ^a   Tang, Yihong ^a,b   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

AGP; HSA; Plasma protein binding; Propafenone; Stereoselectivity

Indexed keywords

APRINDINE; DIAZEPAM; FUROSEMIDE; HUMAN SERUM ALBUMIN; NIFEDIPINE; NIMODIPINE; NITRENDIPINE; OROSOMUCOID; PROPAFENONE; QUINIDINE; VERAPAMIL;

ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CHIRAL CHROMATOGRAPHY; CONTROLLED STUDY; COW; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; ENANTIOMER; ENANTIOSELECTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RABBIT; RACEMIC MIXTURE; RAT; SPECIES COMPARISON; SPECIES DIFFERENCE; STEREOCHEMISTRY; THERMODYNAMICS; ULTRAFILTRATION; VALIDATION PROCESS;

ANIMALS; CIRCULAR DICHROISM; DRUG INTERACTIONS; HUMANS; PLASMA; PROPAFENONE; PROTEIN BINDING; RABBITS; RATS; SPECIES SPECIFICITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349557614     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20666     Document Type: Article

References (26)

1. Stoschitzky K, Klein W, Stark G, Stark U, Zernig G, Graziadei I, Lindner W. Different stereoselective effects of (R)- and (S)-propafenone: clinical pharmacologic, electrophysiologic, and radioligand binding studies. Clin Pharmacol Ther 1990;47:74-746.
2. Chen XY, Zhong DF, Henning B. Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers. Eur J Pharm Sci 2000;10:11-16.
3. Tonn GR, Kerr CR, Axelson JE. In vitro protein binding of propafenone and 5-hydroxypropafenone in serum, in solutions of isolated serum proteins, and to red blood cells. J Pharm Sci 1992;81:1098-1103.
4. Gillis AM, Yee Y-G., Kates RE. Binding of antiarrhythmic drugs to purified human alpha 1-acid glycoprotein. Biochem Pharmacol 1985;34:4279-4282.
5. Oravcová J, Lindner W, Szalay P, Boháčik L, Trnovec T. Interaction of propafenone enantiomers with human alpha 1-acid glycoprotein. Chirality 1991;3:30-34.
6. Šoltés L, Sébille B, Szalay P. Propafenone binding interaction with human alpha 1-acid glycoprotein: assessing experimental design and data evaluation. J Pharm Biomed Anal 1994;12:1295-1302.
7. Puigdemont A, Arboix M, Gaspari F, Bortolotti A, Bonati M. In vitro plasma protein binding of propafenone and protein profile in eight mammalian species. Res Commun Chem Pharmacol 1989;64:435-440.
8. Zhou Q, Yao TW, Zeng S. Chiral reversed phase-high performance liquid chromatography for determining propranolol enantiomers in transgenic Chinese hamster CHL cell lines expressing human cytochrome P450. J Biochem Bioph Meth 2002;54:369-376.
9. Zhou Q, Yao TW, Yu YN, Zeng S. Concentration dependent stereoselectivity of propafenone N-depropylation metabolism with human hepatic recombinant CYP1A2. Die Pharmazie 2003;58:651-653.
10. Wu YJ, Ma MM, Zeng S. Enantioselective assay of S(+)- and R(-)- propafenone in human urine by using RP-HPLC with precolumn chiral derivatization. J Zhejiang Univ Sci 2004;5:226-229.
11. Tang YH, He Y, Yao TW, Zeng S. Simultaneous determination of the enantiomers of esmolol and its acid metabolite in human plasma by reversed phase liquid chromatography with solid-phase extraction. J Chromatogr B 2004;805:249-254.
12. He Y, Zeng S. Determination of the stereoselectivity of chiral drug transport across Caco-2 cell monolayers. Chirality 2006;18:64-69.
13. Whitlam JB, Brown KF. Ultrafiltration in serum protein binding determinations. J Pharm Sci 1981;70:146-150.
14. Jin YX. Master's thesis, Enantioselective binding of chiral drugs, mexiletine and ketoprofen, to plasma proteins. Zhejiang University. 2006.
15. Tang YH. Ph.D. thesis: Enantioselective binding of chiral drugs to plasma proteins. Zhejiang University. 2005.
16. Yamaoka K, Tanigawara T, Nakagawa T, Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 1981;4:879-885.
17. Loun B, Hage DS. Chiral separation mechanisms in protein-based HPLC columns. 1. Thermodynamic studies of (R)- and (S)-warfarin binding to immobilized human serum albumin. Anal Chem 1994;66:3814-3822.
18. Ross PD, Subramanian S. Thermodynamics of protein association ractions: forces contributing to stability. Biochemistry 1984;20:3096-3102.
19. Fournier T, Medjoubi NN, Proquet D. Alpha-1 acid glycoprotein. Biochimica et Biophysica Acta 2000;1482:157-171.
20. Eap CB, Cuendet C, Baumann P. Orosomucoid (alpha-1-acid glycoprotein) phenotyping by use of immobilized pH gradients with 8 M urea and immunoblotting. A new variant encountered in a population study. Hum Genet 1988;80:183-185.
21. Fitos I, Visy J, Zsila F, Bikadi Z, Mady G, Simmomyi M. Specific ligand binding on genetic variants of human α1-acid glycoprotein studied by circular dichroism spectroscopy. Biochem Pharmacol 2004;67: 679-688.
22. Hervé F, Gomas E, Duché JC, Tillement JP. Fractionation of the genetic variants of human a1-acid glycoprotein in the native form by chromatography on an immobilized copper (II) affinity adsorbent. Heterogeneity of the separate variants by isoelectrofocusing and by concanavalin A affinity chromatography. J Chromatogr 1993;615:47-57.
23. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001;33:161-235.
24. 1-acid glycoprotein: generation of a threedimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol Pharmacol 1998; 54:129-138.
25. MacKichan JJ. Protein binding drug displacement interactions fact or fiction. Clin Pharmacokinet 1989;16:65-73.
26. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003;19:822-835.